Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: yosi s who wrote (773)	5/12/1999 8:18:00 PM
From: yosi s	Read Replies (3) of 1386

Notes from Conference Call Dr. Harry Tracy from NeuroInvestment Q - what are details on expecting HU-211 transaction this year? A - Bob Cook - "Timing hasn't changed." Want it done "as soon as possible." In our discussions "We are making the progress we expected to make " Q - what can you say about other R&D projects? A- Gadi Reseinfeld - stroke - we shall not do clinical work , but everything necessary to do IND for the company that will do the clinical work dexanabinol -- we are "generating a platform of possibility" for interested potential partners Q - how many companies in semifinalist categroy for HU-211? A - Gadi Reisenfeld - "enough" - we have no interest in any other companies joining party at this point Q - what is status of line of credit? A - Bob Cook - we drew 1.2 million in first quarter will probably draw same in second quarter we're tring to minimize it to the extent that we can we're going to keep cash at current level and will use credit line only to extent to keep it here Q - what about revival of co-marketing agreement for Alrex? A - we're maintaining dialogue with Bausch & Lomb. we'll be having meeting with them in Tampa in about 3 weeks Q - how many surgical reps detailing products? A - about 65 BOL sales force + 150 in BOL surgical division no direct calls to allergists yet Marvin Porter 1st Associates Q - update on target for European filings? A - we're looking at getting at least one of products filed in Europe this year in Q3 or Q4; hopefully both done. Beginning to see progress getting non-US markets: South America, Canada (ARgentina approval both products already) Private investor Q - market size and launch in Argentina? A -market is small <few million We're viewing it as sign of commitment on part of BOL to get product out globally Pennsylvania Merchant Group -- Phyllis Calista Q - HU-211 what do you want partnership to look like? A - Each of the companies has a slightly different interest in deal structure. One of the biggest differences -- licensing all indications, just stroke and head trauma, just head trauma. The decision on that question drives most of the economic questions going forward. As general target we would like to see commitment to commercialize and market product and for us to get royalties; for them to pick up R&D costs going forward. License fees, milestone payments. Q- Potentially you could have more than one partner??? A - I wouldn't necessarily rule that out. We're trying to get a partner for stroke and head trauma. If that's all they want, we might get more parties for other indications.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next